Serum C-peptide as an indicator of metabolic syndrome in non-diabetic adults: a population-based study

Metabolic syndrome (MetS) and elevated C-peptide both reflect insulin resistance and increased cardiometabolic risk. We assessed whether fasting serum C-peptide can serve as an indicator of MetS in non-diabetic adults from the general population. We analyzed 4,072 adults aged 20–74 years without diabetes from a predominantly white Caucasian population participating in the Healthy Finland 2023 health examination survey. We evaluated the ability of C-peptide to discriminate MetS using receiver operating characteristic (ROC) analyses and identified optimal cut-offs using the Youden index. We compared C-peptide with glycated hemoglobin (HbA1c), high-sensitivity C-reactive protein (hs-CRP), and alanine aminotransferase (ALT), and examined performance separately in obese and non-obese participants. In the full sample, C-peptide discriminated MetS well, with AUCs of 0.80–0.81 across sexes and MetS definitions. Using the International Diabetes Federation (IDF) definition, optimal cut-offs were ≥ 0.66 nmol/L for men and ≥ 0.63 nmol/L for women (sensitivities 72% and 70%; specificities 75% and 76%). C-peptide outperformed HbA1c, ALT, and hs-CRP ( p < 0.05), suggesting its potential as a simple biomarker for early identification of MetS. Discrimination was modestly lower in non-obese participants (AUCs 0.75–0.77 across definitions) and further attenuated in obese participants (AUC 0.73–0.75 across definitions). C-peptide remained the best-performing marker in non-obese participants, whereas among obese participants its performance was comparable to HbA1c. The optimal cut-offs yielded high negative predictive values (84–87%) among non-obese participants, whereas positive predictive values were highest (79–90%) among obese participants. Fasting C-peptide is a promising screening indicator of MetS in non-diabetic adults. It outperformed several commonly used biomarkers and showed good discrimination across sexes and MetS definitions, although further studies are needed to establish its role in clinical practice.

Authors

Institutions

Publication Details

Journal
Diabetology & Metabolic Syndrome
Published
2026-11-19
DOI
https://doi.org/10.1186/s13098-026-02344-4
Primary Topic
Diabetes, Cardiovascular Risks, and Lipoproteins
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Serum C-peptide as an indicator of metabolic syndrome in non-diabetic adults: a population-based study

Susanna Aspholm, Ilkka Vauhkonen, Tero T Saukkonen, Tarja Palosaari et al.
Diabetology & Metabolic Syndrome
Diabetes, Cardiovascular Risks, and Lipoproteins
article

Serum C-peptide as an indicator of metabolic syndrome in non-diabetic adults: a population-based study

Susanna Aspholm, Ilkka Vauhkonen, Tero T Saukkonen, Tarja Palosaari, Hannu Vessari, Linda Mustelin, Annamari Lundqvist, Tuija Jääskeläinen, Aku Ojanen
article en

Abstract

Metabolic syndrome (MetS) and elevated C-peptide both reflect insulin resistance and increased cardiometabolic risk. We assessed whether fasting serum C-peptide can serve as an indicator of MetS in non-diabetic adults from the general population. We analyzed 4,072 adults aged 20–74 years without diabetes from a predominantly white Caucasian population participating in the Healthy Finland 2023 health examination survey. We evaluated the ability of C-peptide to discriminate MetS using receiver operating characteristic (ROC) analyses and identified optimal cut-offs using the Youden index. We compared C-peptide with glycated hemoglobin (HbA1c), high-sensitivity C-reactive protein (hs-CRP), and alanine aminotransferase (ALT), and examined performance separately in obese and non-obese participants. In the full sample, C-peptide discriminated MetS well, with AUCs of 0.80–0.81 across sexes and MetS definitions. Using the International Diabetes Federation (IDF) definition, optimal cut-offs were ≥ 0.66 nmol/L for men and ≥ 0.63 nmol/L for women (sensitivities 72% and 70%; specificities 75% and 76%). C-peptide outperformed HbA1c, ALT, and hs-CRP ( p < 0.05), suggesting its potential as a simple biomarker for early identification of MetS. Discrimination was modestly lower in non-obese participants (AUCs 0.75–0.77 across definitions) and further attenuated in obese participants (AUC 0.73–0.75 across definitions). C-peptide remained the best-performing marker in non-obese participants, whereas among obese participants its performance was comparable to HbA1c. The optimal cut-offs yielded high negative predictive values (84–87%) among non-obese participants, whereas positive predictive values were highest (79–90%) among obese participants. Fasting C-peptide is a promising screening indicator of MetS in non-diabetic adults. It outperformed several commonly used biomarkers and showed good discrimination across sexes and MetS definitions, although further studies are needed to establish its role in clinical practice.

Diabetology & Metabolic Syndrome
Finnish Institute for Health and Welfare (FI), Novo Nordisk (Finland) (FI)
Diabetes, Cardiovascular Risks, and Lipoproteins
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon